Trade

with

NewLink Genetics Corp
(NASDAQ: NLNK)
AdChoices
39.82
+5.32
+15.42%
After Hours :
38.50
-1.32
-3.31%

Open

35.38

Previous Close

34.50

Volume (Avg)

4.19M (809.97k)

Day's Range

34.40-40.99

52Wk Range

16.00-53.48

Market Cap.

1.11B

Dividend Rate ( Yield )

-

Beta

0.00

Shares Outstanding

27.91M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 1.09M

    • Net Income

    • -31.18M

    • Market Cap.

    • 1.11B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -3,128.33

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.00

    • Forward P/E

    • -28.49

    • Price/Sales

    • 833.33

    • Price/Book Value

    • 13.26

    • Price/Cash flow

    • -30.67

      • EBITDA

      • -30.13M

      • Return on Capital %

      • -45.58

      • Return on Equity %

      • -54.46

      • Return on Assets %

      • -45.58

      • Book Value/Share

      • 2.60

      • Shares Outstanding

      • 27.91M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 41.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -1.41

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -8.60

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 11.54

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -3,116.56

            • 39.38

            • Net Profit Margin

            • -3,128.33

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -1,398.40

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.01

              • 0.76

              • Current Ratio

              • 20.28

              • 2.92

              • Quick Ratio

              • 20.16

              • 2.35

              • Interest Coverage

              • -1,228.93

              • 38.02

              • Leverage Ratio

              • 1.17

              • 2.21

              • Book Value/Share

              • 2.60

              • 4.75

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -24.33

                • 277.78

                • P/E Ratio 5-Year High

                • -41.42

                • 634.30

                • P/E Ratio 5-Year Low

                • -4.84

                • 124.82

                • Price/Sales Ratio

                • 769.23

                • 9.35

                • Price/Book Value

                • 12.09

                • 8.50

                • Price/Cash Flow Ratio

                • -30.67

                • 50.25

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -54.46

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -45.58

                    (-61.60)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -53.39

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.01

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -31.14M
                  Operating Margin
                  -2,849.13
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -30.67
                  Ownership

                  Institutional Ownership

                  50.71%

                  Top 10 Institutions

                  34.43%

                  Mutual Fund Ownership

                  32.61%

                  Float

                  60.69%

                  5% / Insider Ownership

                  3.57%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    1,656,147

                  • 0.00

                  • 5.93

                  • SPDR® S&P Biotech ETF

                  •  

                    645,280

                  • 3.60

                  • 3.39

                  • Franklin Biotechnology Discovery

                  •  

                    604,000

                  • 28.07

                  • 2.17

                  • iShares Nasdaq Biotechnology

                  •  

                    370,518

                  • -0.69

                  • 1.95

                  • Vanguard Total Stock Mkt Idx

                  •  

                    317,596

                  • 0.00

                  • 1.14

                  • iShares Russell 2000 (AU)

                  •  

                    309,567

                  • -1.02

                  • 1.63

                  • Fidelity® Select Health Care Portfolio

                  •  

                    280,000

                  • 0.00

                  • 1.00

                  • Franklin Biotechnology Discovery Fund

                  •  

                    268,000

                  • 0.68

                  • 0.96

                  • Fidelity Canadian Growth Company Class

                  •  

                    259,190

                  • 0.00

                  • 0.99

                  • Fidelity Advisor® Biotechnology Fund

                  •  

                    252,479

                  • 0.00

                  • 0.90

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    2,788,591

                  • -4.27%

                  • 9.99

                  • Arnhold & S. Bleichroeder Advisers, LLC

                  •  

                    1,306,970

                  • +12.49%

                  • 4.68

                  • BlackRock Fund Advisors

                  •  

                    1,040,608

                  • +4.14%

                  • 3.73

                  • State Street Corp

                  •  

                    901,120

                  • +5.94%

                  • 3.23

                  • Franklin Advisers, Inc.

                  •  

                    870,200

                  • -0.98%

                  • 3.12

                  • PointState Capital LP

                  •  

                    800,000

                  • -23.44%

                  • 2.87

                  • Pyramis Global Advisors, LLC

                  •  

                    679,430

                  • -8.36%

                  • 2.43

                  • Vanguard Group, Inc.

                  •  

                    540,904

                  • +3.72%

                  • 1.94

                  • TIVERTON ASSET MANAGEMENT LLC

                  •  

                    400,000

                  • 0.00%

                  • 1.43

                  • Wall Street Associates Llc

                  •  

                    282,300

                  • +0.11%

                  • 1.01

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Growth

                  NewLink Genetics Corp., was incorporated in Delaware on June 4, 1999. The Company is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel immunotherapeutic products to improve cancer treat...morement options for patients and physicians. Its products include biologic and small‑molecule immunotherapy product candidates intended to treat oncology indications. Its product candidate, HyperAcute Pancreas cancer immunotherapy, or HyperAcute Pancreas, is being studied in a Phase 3 clinical trial in surgically‑resected pancreatic cancer patients that is being performed under a Special Protocol Assessment, or SPA, with the United States Food and Drug Administration, or FDA. The Company initiated this trial based on encouraging interim Phase 2 data that suggests improvemen...moret in both disease-free and overall survival. The Company has also received Fast Track and Orphan Drug designations from the FDA for this product candidate for the adjuvant treatment of surgically‑resected pancreatic cancer. It has three additional product candidates in clinical development, including its HyperAcute Lung cancer immunotherapy, or HyperAcute Lung, which is being studied in a Phase 1/2 clinical trial at the National Cancer Institute, or NCI, and its HyperAcute Melanoma cancer immunotherapy, or HyperAcute Melanoma, which is being studied in an investigator‑initiated Phase 2 clinical trial. To date, its HyperAcute product candidates have been dosed in more than 200 cancer patients either as a monotherapy or in combination with other therapies and have demonstrated a favorable safety profile. Its HyperAcute product candidates are based on its proprietary HyperAcute immunotherapy technology, which is designed to stimulate the human immune system. Its HyperAcute product candidates use allogeneic (non‑patient specific) cells from previously established cell lines rather than cells derived from the patient. The Company thinks its approach enables a simpler, consistent and scalable manufacturing process than therapies based on patient specific tissues or cells. Its strategy is to discover, develop and commercialize immunotherapeutic products for the treatment of cancer where the needs of patients are unmet by current therapies. The Company faces competition from other public and private biopharmaceutical companies, public and private universities and research organizations actively engaged in the discovery and research and development of products for cancer. The Company is subject to federal, state, local and foreign regulation.lessless

                  Key People

                  Mr. Charles J. Link, Jr

                  CEO/Chairman of the Board/Chief Scientific Officer/Director/Founder

                  Mr. Nicholas N. Vahanian

                  Chief Medical Officer/Co-Founder/President

                  John B. Henneman,III

                  Executive VP/CFO

                  Mr. Mario Mautino

                  Other Corporate Officer/Vice President, Divisional

                  Brian Wiley

                  Vice President, Divisional

                  • NewLink Genetics Corp

                  • 2503 South Loop Drive

                  • Ames, IA 50010

                  • USA.Map

                  • Phone: +1 515 296-5555

                  • Fax: +1 515 296-3520

                  • linkp.com

                  Incorporated

                  1999

                  Employees

                  104

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: